Pharmacogenomics of thymidylate synthase in cancer treatment.

摘要: Cancer drugs such as 5-fluorouracil (5-FU) that target the enzyme thymidylate synthase (TS) have been and are still being widely used in cancer treatment, but with other anti-cancer drugs, majority of tumors do not respond to whereas patients suffer drug-related toxicity. The most recent attempts at improving treatment taken pharmacogenetic approach identifying biochemical response determinants for response, so suboptimal who unlikely can be identified prior treatment. Studies date indicate high intratumoral levels TS gene expression or protein generally predict non-response, low associated a rate. Measuring these requires tumor tissue and, case expression, technically demanding quantitative PCR procedure. Thus, considerable interest was generated by data suggesting variable number 28 base-pair (bp) segment promoter region and/or well 5-FU therapy, toxicity patient survival. However, all studies obtained same results, role this polymorphism predictor outcome is clear currently under evaluation. This review will summarize pharmacogenomic were aimed elucidating function genetic polymorphism.